A nano-liposome formulation of the PARP inhibitor Talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice

Two recently approved PARP inhibitors provide an important new therapeutic option for patients with BRCA-mutated metastatic breast cancer. PARP inhibitors significantly prolong progression-free survival in patients, but conventional oral delivery of PARP inhibitors is hindered by limited bioavailabi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Di, Baldwin, Paige, Leal, Ana S., Carapellucci, Sarah, Sridhar, Srinivas, Liby, Karen T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735511/
https://www.ncbi.nlm.nih.gov/pubmed/31534547
http://dx.doi.org/10.7150/thno.36281

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735511/
https://www.ncbi.nlm.nih.gov/pubmed/31534547
http://dx.doi.org/10.7150/thno.36281

Ejemplares similares